The European Melanoma Registry

“While the total number of cancer incidences is dropping, the number of cases of melanoma is increasing at a rate of 3-7% in many European countries. We need to analyse more data in order to improve diagnosis and develop novel therapies.”

Lidija Kandolf, Serbia

“A rapidly accumulating and massive high-quality real-life data can be obtained only when hands are joined. The conclusions we get from analysing such data allow us to better understand skin cancers and treatment effects. It allows us to formulate burning and important clinical questions and receive the results promptly, in real-time. This is a huge advantage that takes us one step further toward curing cancer. I'm proud to take part in this international collaborative project!”

Nethanel Asher, Israel

“Our advances and success in melanoma research are the result of a true team effort including international collaborations. World class cancer registries are highly needed for patient stratification strategies, as well as in order to translate the results of clinical trials in unselected patient populations and monitor patient care.”

Johanna Mangana, Switzerland

“Real-world data is crucial to validate clinical trial data. Generally, patients enrolled in clinical trials are selected in comparison to patients treated in real life (who are often in worse condition). Analysing data from a large number of real-life patients allows us to assess the true impact of new therapies in clinical practice. This is why a clinical registry such as the European Melanoma Registry is essential.”

Paolo Ascierto, Italy

“In recent years, we have witnessed revolutionary breakthroughs in treatment as well as rejuvenation of patients with melanoma, which poses new challenges for us. EUMelaReg has evolved into a valuable and even more powerful platform for in-depth analysis of clinical practice so far, enabling us to achieve better understanding and successful management of the condition. We are delighted to contribute to global knowledge with data from our real-world practice in Bulgaria.”

Iva Gavrilova, Bulgaria

“The agreement between Germany, Holland and Denmark in December 2017 to establish a European real-world clinical database on metastatic melanoma has proven its value. National databases in several European countries have since been established, and the growing number of patients in the EUMelareg database already have led to significant scientific contributions in the field of real-world evidence. These contributions is of utmost importance to confirm data from pivotal clinical trials on new drugs in melanoma treatment.”

Lars Bastholt, Denmark

“Being part of European Melanoma Registry enables us to gain deeper knowledge that not only refines our diagnosis and treatment strategies but by prioritizing accurate data, we also aim to significantly improve the quality of life and increase the survival rates of melanoma patients.”

Ermira Vasili, Albania

“EUMelaReg is aimed to become the largest melanoma registry in the world. As such, it provides reliable information about relevant questions that clinical trials do not answer.”

Enrique Espinosa, Spain

“The reason I joined EMR is the belief that there is strength in numbers. Collaborating with other European colleagues can generate high quality real world data in order to answer scientific questions, which are not answered in registrational Phase III clinical trials.”

Helen Gogas, Greece

“Real-world data is essential for validating the findings of clinical trials, as patients enrolled in trials often differ significantly from those encountered in everyday clinical practice. By analyzing data from a broad and diverse population in real-world settings, we gain valuable insights into how new therapies perform in practical, day-to-day scenarios. This approach not only helps assess the true effectiveness and safety of treatments but also identifies subpopulations that may benefit most or experience unique challenges. In this context, initiatives like EUMELAREG play a pivotal role by providing a robust infrastructure for collecting and analyzing real-world evidence, bridging the gap between clinical research and routine care, and guiding the optimization of therapeutic strategies in oncology and beyond.”

Vincas Urbonas, Lithuania